The stock of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) is a huge mover today! About 113,788 shares traded hands. Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) has risen 107.55% since March 8, 2016 and is uptrending. It has outperformed by 98.24% the S&P500.
The move comes after 6 months negative chart setup for the $550.06M company. It was reported on Oct, 11 by Barchart.com. We have $17.75 PT which if reached, will make NASDAQ:BLCM worth $44.00M less.
Analysts await Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) to report earnings on November, 14. They expect $-0.62 EPS, down 21.57% or $0.11 from last year’s $-0.51 per share. After $-0.61 actual EPS reported by Bellicum Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 1.64% negative EPS growth.
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) Ratings Coverage
Out of 6 analysts covering Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), 4 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 67% are positive. Bellicum Pharmaceuticals Inc has been the topic of 9 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The stock has “Hold” rating given by Zacks on Wednesday, August 19. The firm has “Buy” rating by SunTrust given on Friday, June 3. As per Friday, June 3, the company rating was initiated by Suntrust Robinson. Citigroup initiated the stock with “Buy” rating in Friday, July 24 report. Jefferies maintained it with “Buy” rating and $22 target price in Tuesday, August 9 report. The rating was maintained by Citigroup on Tuesday, August 9 with “Neutral”. The stock of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) earned “Buy” rating by Guggenheim on Friday, September 11. The stock has “Sell” rating given by Zacks on Monday, September 21. On Thursday, February 25 the stock rating was initiated by Citigroup with “Neutral”.
According to Zacks Investment Research, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas.”
More important recent Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on December 18, 2014, also Fool.com published article titled: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Juno Therapeutics, Inc.”, Fool.com published: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Celldex Therapeutics” on August 03, 2016. More interesting news about Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) was released by: Quotes.Wsj.com and their article: “News Bellicum Pharmaceuticals Inc.BLCM” with publication date: December 13, 2014.
BLCM Company Profile
Bellicum Pharmaceuticals, Inc., incorporated on July 14, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Firm uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Firm is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. The Company’s CID technologies include CaspaCIDe, CIDeCAR and GoCAR-T.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.